<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051696</url>
  </required_header>
  <id_info>
    <org_study_id>LZi</org_study_id>
    <nct_id>NCT05051696</nct_id>
  </id_info>
  <brief_title>Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies</brief_title>
  <official_title>Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liu Zi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Science Center of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic&#xD;
      viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or&#xD;
      recurrent gynecological malignancies. And further research the mechanism of oncolytic viruses&#xD;
      H101.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with recurrent, radiation/chemotherapy-resistant gynecological cancer carry a poor&#xD;
      prognosis. H101 is a recombinant human type-5 adenovirus (Ad5), in which the E1B and E3 gene&#xD;
      have been deleted. Previous studies have shown that H101 has anticancer activity and safety&#xD;
      in some solid tumors, but has little report in gynecological oncology. In this clinical&#xD;
      trial, 60 recurrent or refractory gynecological cancer patients will be enrolled. Based on&#xD;
      individual conditions, all eligible patients are intra-tumor injected oncolytic viruses H101&#xD;
      within 5 consecutive days combined with or without radiotherapy in sequential, three weeks&#xD;
      for a cycle (1-4 cycles totally). Simultaneously, the tumor sample, peripheral blood, and&#xD;
      urine specimen were collected on day1 and day5. Local control rate and side effects are&#xD;
      recorded respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control (LC)</measure>
    <time_frame>3 months</time_frame>
    <description>LC will be measured from the start date of injection until the date of progressive disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 year after injection</time_frame>
    <description>ORR is the percentage of participants with presence of complete response (CR), partial response (PR). ORR assessment will be based on RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Progress free survival is defined as the time from first day of injection until the first date of either objective disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>At day 3, 7 and 30</time_frame>
    <description>Toxicity were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Genital Neoplasms, Female</condition>
  <arm_group>
    <arm_group_label>Oncorine (H101) with or without radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10^11 virus particles(VP) for if tumor diameter≤5cm; 1×10^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10^12 VP for the tumor diameter&gt;10cm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H101</intervention_name>
    <description>Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)</description>
    <arm_group_label>Oncorine (H101) with or without radiotherapy</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
          -  Age ≥ 18 years at the time of study entry.&#xD;
&#xD;
          -  Histological or Cytologically diagnosed gynecological malignancies.&#xD;
&#xD;
          -  Failure to prior standard treatment (surgery, chemotherapy, radiotherapy);&#xD;
&#xD;
          -  Refractory/recurrence/metastasis gynecological cancer&#xD;
&#xD;
          -  At least one measurable lesion according to the RECIST1.1.&#xD;
&#xD;
          -  Cooperative Oncology Group-Status (ECOG Status) 0-3.&#xD;
&#xD;
          -  The last treatment should be over 2 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or evidence of active autoimmune disease that requires systemic treatment.&#xD;
&#xD;
          -  Participated in other anti-tumor clinical trials within 4 weeks.&#xD;
&#xD;
          -  Patients who have a contraindication to similar drugs.&#xD;
&#xD;
          -  That failure to follow up regularly.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zi Liu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zi Liu, M.D</last_name>
    <phone>86-18991232167</phone>
    <email>liuzmail@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi-ying Zhang, M.D</last_name>
    <phone>86-18984240901</phone>
    <email>646186543@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiao Tong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zi liu, Ph.D</last_name>
      <phone>+8613630223132</phone>
      <email>liuzmail@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 11, 2021</study_first_submitted>
  <study_first_submitted_qc>September 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Health Science Center of Xi'an Jiaotong University</investigator_affiliation>
    <investigator_full_name>Liu Zi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cervical Cancer</keyword>
  <keyword>Ovary Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Vaginal Neoplasms</keyword>
  <keyword>Vulvar Neoplasms</keyword>
  <keyword>H101</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

